J.P. Morgan Raises PT on Genomic Health to $18 (GHDX)

J.P. Morgan is out with its report today on Genomic Health GHDX, raising its price target from $17 to $18. In a note to clients, J.P. Morgan writes, "While encouraged at the continued top-line growth, pipeline progress, and commitment to profitability, we continue to be Neutral on GHDX, given the company's preference for reinvestment over operating leverage and profit growth. We apply a 2.2x EV/sales multiple to our 2011 sales estimate to arrive at our December 2011 price target of $18, which we feel adequately discounts the near-term headwinds with the long-term opportunities." Shares of GHDX closed yesterday at $23.32.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetAnalyst RatingsBiotechnologyGenomic HealthHealth CareJ.P. Morgan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!